64951-08-2

Basic information

• Product Name: IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB010195;ASINEX-REAG BAS 06100978;CHEMBRDG-BB 4401038;IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID;AKOS BBS-00006401;1H-Imidazo[1,2-a]pyridine-2-carboxylic acid;H-imidazo[1,2-a]pyridine-2-carboxylic acid;Imidazo[1,2-a]pyridine-2-carboxylic acid ,97%
• CAS NO: 64951-08-2
• Molecular Formula: C₈H₆N₂O₂
• Molecular Weight: 162.15
• Product Categories: pharmacetical;Carboxylic Acids;Carboxylic Acids;Fused Ring Systems;Building Blocks;Imidazo[x,x-y]pyridine;Heterocycle-Pyridine series
• Mol File: 64951-08-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 232-234℃
• Appearance: White to off-white/Powder
• Density: 1.41 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -4.33±0.41(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(64951-08-2)
• EPA Substance Registry System: IMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLIC ACID(64951-08-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-36-22
• Safety Statements: 26-36/37/39-22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 64951-08-2(Hazardous Substances Data)

Usage

Chemical Properties

White to off-white solid

InChI:InChI=1/C8H6N2O2/c11-8(12)6-5-10-4-2-1-3-7(10)9-6/h1-5H,(H,11,12)/p-1

Upstream product

• 504-29-0 2-aminopyridine 
• 1113-59-3 bromopyruvic acid 
• 38922-77-9 ethyl 3-imidazo[1,2-a]pyridine-2-carboxylate 

Downstream Products

• 129799-82-2 2-[2-methoxymethyl-4-(3,4,5-trimethoxybenzyl)piperazin-1-ylcarbonyl]imidazo[1,2-a]-pyridine 
• 1232028-24-8 imidazo[1,2-a]pyridine-2-carboxylic acid {2-[4-(5-fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethyl}-amide 
• 1367714-16-6 C₂₀H₂₀F₂N₄O 
• 15833-22-4 N-phenylimidazo[1,2-a]pyridine-3-carboxamide 
• 1398582-85-8 3-({[(1R)-1-(4-fluorophenyl)ethyl](imidazo[1,2-a]pyridin-2-ylcarbonyl)amino}methyl)benzoic acid 
• 1398584-64-9 C₂₅H₂₂FN₃O₃ 
• 1245711-49-2 N-(tetrahydro-2H-pyran-4-yl)-N-[3-(trifluoromethoxy)benzyl]imidazo[1,2-a]pyridine-2-carboxamide 
• 1227190-80-8 N-[3-(5-{[(1S)-1-cyclohexyl-2-(methylamino)-2-oxoethyl]carbamoyl}furan-2-yl)benzyl]imidazo[1,2-a]pyridine-2-carboxamide 
• 917364-11-5 5,6,7,8-tetrahydroimidazo [1,2-a]pyridine-2-carboxylic acid 

Relevant articles and documents

Structural modification of zolpidem led to potent antimicrobial activity in imidazo[1,2-: A] pyridine/pyrimidine-1,2,3-triazoles

Ambien (zolpidem), an imidazo[1,2-a]pyridine derivative, is a commercial drug to treat insomnia which also possesses antitubercular activity against Mycobacterium tuberculosis H37Rv. In this paper, we describe the synthesis of three diverse lead series of imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles (IPTs) which are designed by specific structural modifications of zolpidem. Most of the IPTs exhibited remarkable in vitro antitubercular activity with an MIC of 1.56 μg mL-1, which is two-fold higher than the MIC of zolpidem. Further, the synthesized IPTs displayed moderate inhibitory activity against several bacterial and fungal strains as well, and also showed an acceptable safety profile as verified through in vitro cytotoxicity assessment against Vero cells. In addition, the potent IPTs exhibited promising binding interactions within the active site of the InhA enzyme. An interesting correlation between the in vitro inhibitory activity and the binding mode was observed: most of the potent molecules (MIC = 1.56 μg mL-1) interact through a H-bond with the Tyr 158 residue of the target enzyme. These efforts toward the structural modification of zolpidem could be helpful for further optimization of the IPT core to develop new anti-TB drugs.

Identification of fused bicyclic heterocycles as potent and selective 5-HT2A receptor antagonists for the treatment of insomnia

A series of fused bicyclic heterocycles was identified as potent and selective 5-HT2A receptor antagonists. Optimization of the series resulted in compounds that had improved PK properties, favorable CNS partitioning, good pharmacokinetic properties, and significant improvements on deep sleep (delta power) and sleep consolidation.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.